Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY3300054 |
Synonyms | |
Therapy Description |
LY3300054 (lodapolimab), is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29712568). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY3300054 | Lodapolimab | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 124 | LY3300054 (lodapolimab), is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29712568). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02791334 | Phase I | LY3300054 + Necitumumab LY3300054 + Ramucirumab LY3300054 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT) | Completed | USA | FRA | ESP | CAN | BEL | 2 |